Danielson M, Kjellberg J, Ohman P, Wernersson B
Acta Med Scand. 1983;214(5):373-80. doi: 10.1111/j.0954-6820.1983.tb08611.x.
Despite the short plasma half-life of hydralazine, once daily Slow Apresoline has been shown to maintain blood pressure control in well controlled hypertension. In the present investigation of 118 inadequately controlled hypertensives, we have shown that 50-150 mg Slow Apresoline once daily induces a significant blood pressure reduction and is well tolerated. Normotension, i.e. supine diastolic blood pressure less than 95 mmHg, was reached in 53% of the patients. Normotension or a supine diastolic blood pressure reduction of greater than or equal to 10 mmHg was achieved in 72% of the patients, the hydralazine responders. Sixteen patients discontinued treatment due to symptoms probably related to hydralazine. Acetylator phenotyping showed that slow acetylators predominated in the group of patients discontinuing hydralazine due to side-effects. In contrast, 90% of the phenotyped non-responders were rapid acetylators, which suggests a suboptimal use of hydralazine in some rapid acetylators.
尽管肼屈嗪的血浆半衰期较短，但每日一次服用缓释阿普利索林已被证明能在血压控制良好的高血压患者中维持血压稳定。在本次针对118例血压控制不佳的高血压患者的研究中，我们发现每日一次服用50 - 150毫克缓释阿普利索林可显著降低血压，且耐受性良好。53%的患者达到了正常血压，即仰卧位舒张压低于95毫米汞柱。72%的患者（即肼屈嗪反应者）达到了正常血压或仰卧位舒张压降低大于或等于10毫米汞柱。16例患者因可能与肼屈嗪相关的症状而停药。乙酰化表型分析显示，在因副作用而停用肼屈嗪的患者组中，慢乙酰化者占主导。相比之下，90%的表型无反应者是快乙酰化者，这表明在一些快乙酰化者中肼屈嗪的使用并不理想。
